A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

NCT06384547 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease

Interventions

DRUG: VRDN-001 10 mg/kg
DRUG: VRDN-001 3 mg/kg

Sponsor

Viridian Therapeutics, Inc.